TAP ENTERS INTO CO-PROMOTION AGREEMENT FOR FAMVIR

TAP Pharmaceutical Products Inc. announced that it has entered into a co-promotion agreement with Novartis Pharmaceuticals Corporation to co-promote Famvi (famciclovir), an oral antiviral prescription medication. Under the terms of the agreement, TAP will be responsible for promoting Famvir to the Obstetrician/Gynecology (OB/GYN) medical community.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=6241549)